Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study

- Study met all primary and key secondary endpoints - Safety profile consistent with prior lebrikizumab studies in atopic dermatitis - Global regulatory submissions to occur next year based on data from the Phase 3 clinical trial program INDIANAPOLIS , Dec.